Fennec Pharmaceuticals (FENC) Granted U.S. Patent for Use of PEDMARK

Go back to Fennec Pharmaceuticals (FENC) Granted U.S. Patent for Use of PEDMARK

Fennec Announces Issuance of U.S. Patent for Use of PEDMARKā„¢

March 5, 2020 7:01 AM EST

RESEARCH TRIANGLE PARK, N.C., March 05, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent 10,596,190 entitled Method for Reducing Ototoxicity in Pediatric Patients Receiving Platinum-Based Chemotherapy.  As suggested by the title, the patent captures the use of Fennecs PEDMARK product to reduce the ototoxic effects of cisplatin in pediatric... More